Integrins as therapeutic targets in the organ-specific metastasis of human malignant melanoma

Table 1 The responsible integrins for the organ-specific metastasis of human melanoma and the inhibitors of these integrins

Integrin	Metastatic site	Inhibitor
α4	Lymph node [55]	TBC3486 [141] JK273 [144] Natalizumab (Antegren) [139, 140]
α4β1	Lymph node [29, 53, 55, 138], bone [98]	TBC3486 [141] JK273 [144]
β1	Lymph node [18, 53, 138]	AIIB2 [145]
α2	Liver [92]	–
α2β1	Lung [82], liver [82]	BTT-3033, BTT-3034 [146]
α5β1	Liver [96]	Volociximab (M200) [128] ATN-161 [95, 133,134,135] PF-04605412 [137]
β3	Bone [101]	Abergrin (eteracizumab, MEDI-522) [121, 122] MK-0429 [76]
αv	Brain [110]	Intetumumab (CNTO 95) [113] Cilengitide (EMD 121974) [120]
αvβ3	Lung [76], bone [97], brain [108, 111],	MK-0429 [76] Abergrin (eteracizumab, MEDI-522) [121, 122] Cilengitide (EMD 121974) [120]

ISSN: 1756-9966